For C2-GBM, CD532 (targeting AURKA) and BI-2536 (targeting PLK1) showed efficacy in over 30 GBM cell lines, indicating their suitability for this subtype (Figure 8C, Table S2). This evidence concerns the gene PLK1 and glioblastoma.